Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04260152 · ClinicalTrials.gov registry record · NA

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

A NA study of Gingival Recession, sponsored by Geistlich Pharma.

Completed
Registry status
NA
Development phase
30
Enrollment target
3
Study locations

NCT04260152: Completed NA study of Gingival Recession, sponsored by Geistlich Pharma.

NCT04260152 is a NA study of Gingival Recession that has completed, run by Geistlich Pharma. The registered enrollment target is 30 participants, roughly in line with the 31-participant average among 10 other Gingival Recession trials with a reported enrollment target. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04260152, a NA study of Gingival Recession, has completed, sponsored by Geistlich Pharma.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

Primary Outcome

Change in percent root coverage compared to baseline

Conditions Studied

Gingival Recession

Interventions

  • DEVICE Geistlich Fibro-Gide
  • PROCEDURE Connective Tissue Graft (CTG

Study Locations (3)

Michigan

  • Seven Lakes Periodontitis - Fenton

Texas

  • Perio Health Professionals - Houston

Washington

  • Oral Health Specialists - Tacoma

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-09-01
Est. Completion 2020-07-22
Phase NA
Geistlich Pharma

5 total trials

What the finished NCT04260152 record still lists

NCT04260152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, roughly in line with the 31-participant average among 10 other Gingival Recession trials with a reported enrollment target.

The record links to 1 condition, with Gingival Recession appearing as the primary indexed condition, and to 2 interventions - of which Geistlich Fibro-Gide is the first listed.

NCT04260152 reports a single indexed study location in Michigan, Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT04260152 about?

NCT04260152 is a clinical study titled "Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months". This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

What is the current status of trial NCT04260152?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-01. Estimated completion is 2020-07-22.

What conditions does trial NCT04260152 study?

This clinical trial studies the following conditions: Gingival Recession.

What interventions are being tested in trial NCT04260152?

The interventions under investigation include: Geistlich Fibro-Gide (DEVICE), Connective Tissue Graft (CTG (PROCEDURE).

Who is sponsoring clinical trial NCT04260152?

This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04260152 being conducted?

This trial has 3 study locations across Michigan, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gingival Recession

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04260152's enrollment target sits among peer trials

30 6th of 10 higher than 5 of 10 other Gingival Recession trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gingival Recession trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04260152, the US trial registry maintained by the National Library of Medicine. NCT04260152 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.